Objective: To evaluate the impact of phenol-based insulin-excipient induced inflammation on insulin pharmacokinetic (PK) variability in diabetic mice and to evaluate effects of anti-inflammatory agents (dexamethasone and cromolyn) in minimizing excipient induced inflammation.

Methods: Using a modified murine air pouch model, saline or insulin excipients were continuously infused for durations of 1 and 3 days. Subsequently, a single subcutaneous insulin injection of 0.3U (1:100; Humalog) was placed into the air pouch. Blood samples were taken periodically. Bioanalysis was done by ELISA for PK evaluation. A separate analysis determined effects of anti-inflammatory agents co-infused with insulin on maintaining glycemia during infusion pump therapy while extending its lifespan. Tissue was analyzed by standard histopathology (H and E).

Results: Primary PK values Cmax, Tmax, AUC (0-120) for saline and excipient infused groups are depicted in Figure 1A and 1B. The excipient group demonstrated lower Tmax, AUC (0-120) and Cmax as compared to saline group. Figure 1C depicts a significantly greater degree of inflammation in all excipient treated groups. Usage of co-infusion with anti-inflammatory agents extends insulin infusion set lifespan.

Conclusion: Insulin excipients induce site specific inflammation that alters insulin PK and diminishes the in vivo insulin bioavailability. Confirmation in a porcine model is underway.


M.K. Hidau: None. C. Kesserwan: None. Y. Qiao: None. D. Kreutzer: Other Relationship; Self; Abbott Laboratories, cell and molecualar tissue enginnering (cmte). U. Klueh: Research Support; Self; Abbott. Other Relationship; Self; Cell and Molecular Tissue Engineering, LLC.


The Leona M. and Harry B. Helmsley Charitable Trust

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.